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Interventions UGT1A1*28 genotyping was compared with no genotyping for patients with metastatic colorectal cancer.
With no genotyping, patients with no haematological side-effect during the first course of combined 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) received the same dose 15 days later for the second course of treatment. Patients with grade three or four neutropenia during the first course, received a FOLFIRI dose reduced by 25% for the second course. Those with febrile neutropenia during the first course, switched to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX).
With genotyping, patients found to be homozygous for the UGT1A1*28 variant (genotype 7/7) were given colonystimulating factor to reduce the risk of chemotherapy-induced neutropenia during the first course of FOLFIRI, and then received the same FOLFIRI dose 15 days later. Patients with the variants UGT1A1*1/*1 (genotype 6/6) and *1/*28 (genotype 6/7) were given no prophylaxis and the same treatment as those who were not genotyped.
Location/setting
France/secondary care.
Methods

Analytical approach:
A decision-tree model was used and populated with data from the literature. The time horizon was from the initiation of genotyping until the end of the second course of chemotherapy. The authors reported that a hospital perspective was adopted.
Effectiveness data:
The effectiveness data were from published studies. The estimated probabilities for each outcome were identified by literature review in the MEDLINE database. The primary clinical outcome was the probability that patients would have a haematological side-effect, given their genotype and the treatment received.
Monetary benefit and utility valuations:
